Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. This phase II trial is studying how well dasatinib works in treating patients with
stage IIIB, stage IV, or recurrent non-small cell lung cancer.